NPRL2 Antibody (H-8): sc-166969

NPRL2 Antibody (H-8) is a mouse monoclonal IgG2b antibody that detects NPRL2 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). NPRL2, also known as TUSC4 (tumor suppressor candidate 4), is a 380 amino acid protein characterized by a bipartite nuclear localization signal and a granulin protein-binding domain, which are crucial for its function in cellular processes. NPRL2 is predominantly expressed in skeletal muscle, with significant levels also found in the brain, liver, and pancreas, while lower expression is noted in the lung, kidney, placenta, and heart. NPRL2 is particularly relevant in the context of cancer, as NPRL2 is expressed in most lung cancer cell lines and is believed to play a role in tumor suppression, mismatch repair, and cell cycle checkpoint signaling. Notably, NPRL2 may enhance the therapeutic efficacy of chemotherapy drugs, such as cisplatin, by resensitizing patients who have developed resistance to this treatment. The gene encoding NPRL2 is conserved across species and produces two isoforms due to alternative splicing, highlighting its evolutionary significance and potential as a target for therapeutic intervention. Anti-NPRL2 antibody (H-8) is an essential tool for researchers investigating the molecular mechanisms underlying cancer biology and therapeutic resistance.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

NPRL2 Antibody (H-8) References:

1. NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway.  |  Jayachandran, G., et al. 2010. PLoS One. 5: e11994. PMID: 20700484
2. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1.  |  Bar-Peled, L., et al. 2013. Science. 340: 1100-6. PMID: 23723238
3. Relationship between tumor and peripheral blood NPRL2 mRNA levels in patients with colorectal adenoma and colorectal cancer.  |  Liu, AY., et al. 2014. Cancer Biol Ther. 15: 489-95. PMID: 24521741
4. Decreased expression of NPRL2 in renal cancer cells is associated with unfavourable pathological, proliferation and apoptotic features.  |  Tang, Y., et al. 2014. Pathol Oncol Res. 20: 829-37. PMID: 24789683
5. Biological characteristics of renal cancer cells after CTP-mediated cancer suppressor gene NPRL2 protein treatment.  |  Zeng, Y., et al. 2016. Biol Chem. 397: 1163-1171. PMID: 27186678
6. KLHL22 activates amino-acid-dependent mTORC1 signalling to promote tumorigenesis and ageing.  |  Chen, J., et al. 2018. Nature. 557: 585-589. PMID: 29769719
7. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.  |  Luo, S., et al. 2020. Exp Cell Res. 390: 111981. PMID: 32234375
8. FOXO1 inhibits prostate cancer cell proliferation via suppressing E2F1 activated NPRL2 expression.  |  Tang, Y., et al. 2021. Cell Biol Int. 45: 2510-2520. PMID: 34459063
9. Bioinformatics analysis of the prognostic and immunotherapeutic significance of NPRL2 in stomach adenocarcinoma.  |  Pi, Y., et al. 2022. J Gastrointest Oncol. 13: 1589-1604. PMID: 36092347
10. NPRL2 down-regulation facilitates the growth of hepatocellular carcinoma via the mTOR pathway and autophagy suppression.  |  Wang, YC., et al. 2022. Hepatol Commun. 6: 3563-3577. PMID: 36321403

The preferred NPRL2 antibody is NPRL2 Antibody (F-3): sc-376986.